ARTICLE | Emerging Company Profile
With Medicxi’s backing, Vaderis taking industry’s first shot at rare vascular disorder
European VC’s series A investment to fund start-up’s clinical evaluation of AKT inhibitor for hereditary hemorrhagic telangiectasia
August 22, 2022 7:50 AM UTC
Quietly backed by Medicxi since 2020, Vaderis has begun a proof-of-concept study that could position its lead program as a first-to-market product for a rare vascular overgrowth disorder.
Basel-based Vaderis Therapeutics AG is advancing AKT inhibitor VAD044 into the Phase Ib INSIGHT trial to treat hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome...